# Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

> **NCT07223411** · — · RECRUITING · sponsor: **John Kirkwood** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Melanoma

## Interventions

- **DRUG:** Fianlimab + Cemiplimab
- **DRUG:** Relatlimab + Nivolumab

## Key facts

- **NCT ID:** NCT07223411
- **Lead sponsor:** John Kirkwood
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2028-11-01
- **Final completion:** 2031-11-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223411, "Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07223411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*